Evidence map›Paper›PMID 39937961›Full record

Observational studyHematological oncology2025

Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.

Yuma Nato, Kana Miyazaki, Dai Maruyama, Hiroyuki Takahashi, Kazutaka Sunami, Satsuki Murakami, Eiju Negoro, Yuri Miyazawa, Ilseung Choi, Takahiro Okada and 27 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Elevated circulating CD10Annals of hematology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Yuma NatoDepartment of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0001-6547-3181
Dai MaruyamaDepartment of Hematology Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0654-6920
Hiroyuki TakahashiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Kazutaka SunamiDepartment of Hematology, NHO Okayama Medical Center, Okayama, Japan.
Satsuki MurakamiDepartment of Hematology, Aichi Medical University, Nagakute, Japan.
Eiju NegoroDepartment of Hematology and Oncology, University of Fukui, Fukui, Japan.
Yuri MiyazawaDepartment of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Ilseung ChoiDepartment of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-8920-7045
Takahiro OkadaDepartment of Hematology and Oncology, Shimane University School of Medicine, Izumo, Japan.
Nobuyuki TakayamaDepartment of Hematology, Kyorin University Faculty of Medicine, Mitaka, Japan.
Naoto TomitaDepartment of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yuto KanedaDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Masahiro YoshidaDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Hiroshi GomyoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Kohtaro ToyamaDepartment of Hematology, Fujioka General Hospital, Gunma, Japan.
Momoko NishikoriDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akio SaitoDepartment of Hematology, NHO Shibukawa Medical Center, Gunma, Japan.
Junji HiragaDepartment of Hematology, Toyota Kosei Hospital, Toyota, Japan.
Taro MasunariDepartment of Hematology/Infectious Diseases, Chugoku Central Hospital, Fukuyama, Japan.
Naoki TakahashiDepartment of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan.
Junya MakiyamaDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Tomotaka SuzukiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hiroko TsunemineDepartment of Hematology, Shinko Hospital, Kobe, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Yasufumi MasakiDepartment of Hematology and Immunology, Kanazawa Medical University, Kahoku-gun, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Masataka OkamotoDepartment of Hematology and Oncology, Fujita Health University Okazaki Medical Center, Okazaki, Japan.
Isao TawaraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Naoko AsanoDepartment of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Ritsuro SuzukiDepartment of Hematology and Oncology, Shimane University School of Medicine, Izumo, Japan.
Motoko YamaguchiDepartment of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0002-7094-6489

Funding

Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research JP21K08412National Cancer Center Research and Development Fund 2023-J-03
6 · The paper itself

Abstract

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and high-dose methotrexate (HD-MTX) (DA-EPOCH-R/HD-MTX) showed excellent efficacy and manageable safety in a phase II study of patients diagnosed with stage II-IV CD5+ DLBCL. To validate the results of that study and elucidate the current state of treatment for CD5+ DLBCL, we retrospectively analyzed the outcomes of patients with CD5+ DLBCL diagnosed between 2016 and 2021 who received anthracycline-containing chemotherapy with rituximab. Among the 346 patients evaluated, 62 (18%) received DA-EPOCH-R/HD-MTX. The median follow-up time was 43 months. In 55 patients with stage II-IV disease treated with DA-EPOCH-R/HD-MTX, the 2-year overall survival (OS), progression-free survival, and cumulative incidence of CNS relapse were 87% (95% CI, 73%-94%), 76% (95% CI, 61%-86%), and 7.3% (95% CI, 2.4%-16%), respectively. There were no treatment-related deaths. Febrile neutropenia occurred in 18 (33%) patients. Multivariate analysis of the 346 patients identified elevated serum lactate dehydrogenase levels, multiple extranodal involvement, no intrathecal MTX (IT-MTX), and no DA-EPOCH-R/HD-MTX as independent risk factors for OS. Only one CNS relapse event was observed in 28 patients who received both HD-MTX and IT-MTX. Our study provides real-world data on the treatments and outcomes of a large number of patients. The favorable survival and manageable toxicity of DA-EPOCH-R/HD-MTX have been validated in clinical settings. The use of HD-MTX and IT-MTX might be effective for preventing CNS relapse in patients with CD5+ DLBCL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCD5 AntigensLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclophosphamideDoxorubicinEtoposideFemaleHumansMaleMethotrexateMiddle AgedPrednisonePrognosisCD5 AntigensCyclophosphamideDoxorubicinEtoposideMethotrexatePrednisoneRituximabVincristineCD5 antigencentral nervous system neoplasmsdiffuse large B‐cell lymphomamethotrexateretrospective study

Identifiers

PMID39937961
PMCPMC11819764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.